Gain Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Gain Therapeutics Stock-Based Compensation Growth & History (GANX)
Gain Therapeutics's stock-based compensation was $1.8M for fiscal 2025.
View full Gain Therapeutics company overviewGain Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.8M | −$586,964 | −24.56% |
| 2024 | 2024-12-31 | $2.4M | −$868,867 | −26.66% |
| 2023 | 2023-12-31 | $3.3M | $1.7M | +113.51% |
| 2022 | 2022-12-31 | $1.5M | $687,063 | +81.85% |
| 2021 | 2021-12-31 | $839,371 | $757,731 | +928.14% |
| 2020 | 2020-12-31 | $81,640 | — | — |
Gain Therapeutics quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $566,050 | $44,031 | +8.43% |
| Q1 2026 | 2026-03-31 | $403,509 | −$15,995 | −3.81% |
| Q4 2025 | 2025-12-31 | $401,667 | $42,338 | +11.78% |
| Q3 2025 | 2025-09-30 | $460,005 | $102,500 | +28.67% |
| Q2 2025 | 2025-06-30 | $522,019 | −$960,882 | −64.80% |
| Q1 2025 | 2025-03-31 | $419,504 | $229,080 | +120.30% |
| Q4 2024 | 2024-12-31 | $359,329 | −$195,730 | −35.26% |
| Q3 2024 | 2024-09-30 | $357,505 | −$549,822 | −60.60% |
| Q2 2024 | 2024-06-30 | $1.5M | $251,693 | +20.44% |
| Q1 2024 | 2024-03-31 | $190,424 | −$375,008 | −66.32% |
| Q4 2023 | 2023-12-31 | $555,059 | −$3,633 | −0.65% |
| Q3 2023 | 2023-09-30 | $907,327 | $551,680 | +155.12% |
| Q2 2023 | 2023-06-30 | $1.2M | $925,658 | +302.95% |
| Q1 2023 | 2023-03-31 | $565,432 | $258,887 | +84.45% |
| Q4 2022 | 2022-12-31 | $558,692 | $272,432 | +95.17% |
| Q3 2022 | 2022-09-30 | $355,647 | $104,822 | +41.79% |
| Q2 2022 | 2022-06-30 | $305,550 | $113,989 | +59.51% |
| Q1 2022 | 2022-03-31 | $306,545 | $195,820 | +176.85% |
| Q4 2021 | 2021-12-31 | $286,260 | — | — |
| Q3 2021 | 2021-09-30 | $250,825 | — | — |
| Q2 2021 | 2021-06-30 | $191,561 | — | — |
| Q1 2021 | 2021-03-31 | $110,725 | — | — |
Gain Therapeutics stock-based compensation trends
Over the last five fiscal years, Gain Therapeutics's stock-based compensation increased from $81,640 to $1.8M, a change of $1.7M. The latest reported quarter, Q2 2026, shows $566,050.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gain Therapeutics source filings ↗